Kleiman, N.S.

patient trial event eptifibatide infarction investigator thrombocytopenia intervention pursuit study death platelet treatment 30 days percutaneou /iiia therapy group table placebo site investigators outcome end-point syndrome glycoprotein strategy committee elevation pursuit trial effect enzyme angina baseline heparin revascularization state reduction end point result randomized treatment effect point population receptor incidence complication procedure heart site investigator circulation ck-mb model analysis event rates events committee adjudication definition difference safety enrolment mortality califf rm 72 hours swets subs service research topol ej assessment america ischemic disagreement nadir timing benefit review management criteria infusion characteristic count topol